ALX Oncology (ALXO) Competitors $1.22 +0.14 (+12.96%) Closing price 04:00 PM EasternExtended Trading$1.16 -0.05 (-4.51%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALXO vs. HUMA, SOPH, FENC, TLSA, AVTE, PRQR, TRDA, SGMT, ENGN, and GNFTShould you be buying ALX Oncology stock or one of its competitors? The main competitors of ALX Oncology include Humacyte (HUMA), SOPHiA GENETICS (SOPH), Adherex Technologies (FENC), Tiziana Life Sciences (TLSA), Aerovate Therapeutics (AVTE), ProQR Therapeutics (PRQR), Entrada Therapeutics (TRDA), Sagimet Biosciences (SGMT), enGene (ENGN), and GENFIT (GNFT). These companies are all part of the "pharmaceutical products" industry. ALX Oncology vs. Its Competitors Humacyte SOPHiA GENETICS Adherex Technologies Tiziana Life Sciences Aerovate Therapeutics ProQR Therapeutics Entrada Therapeutics Sagimet Biosciences enGene GENFIT ALX Oncology (NASDAQ:ALXO) and Humacyte (NASDAQ:HUMA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, media sentiment, valuation and institutional ownership. Does the media refer more to ALXO or HUMA? In the previous week, ALX Oncology and ALX Oncology both had 4 articles in the media. Humacyte's average media sentiment score of 1.36 beat ALX Oncology's score of 0.90 indicating that Humacyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ALX Oncology 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Humacyte 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, ALXO or HUMA? ALX Oncology has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500. Comparatively, Humacyte has a beta of 1.87, indicating that its share price is 87% more volatile than the S&P 500. Which has preferable valuation and earnings, ALXO or HUMA? ALX Oncology has higher earnings, but lower revenue than Humacyte. Humacyte is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioALX OncologyN/AN/A-$134.85M-$2.20-0.55Humacyte$1.57M144.25-$148.70M-$0.45-3.18 Do insiders and institutionals hold more shares of ALXO or HUMA? 98.0% of ALX Oncology shares are held by institutional investors. Comparatively, 44.7% of Humacyte shares are held by institutional investors. 21.0% of ALX Oncology shares are held by company insiders. Comparatively, 5.1% of Humacyte shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Do analysts prefer ALXO or HUMA? ALX Oncology currently has a consensus price target of $3.30, suggesting a potential upside of 170.49%. Humacyte has a consensus price target of $9.75, suggesting a potential upside of 581.82%. Given Humacyte's stronger consensus rating and higher probable upside, analysts clearly believe Humacyte is more favorable than ALX Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ALX Oncology 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Humacyte 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00 Is ALXO or HUMA more profitable? Humacyte's return on equity of 0.00% beat ALX Oncology's return on equity.Company Net Margins Return on Equity Return on Assets ALX OncologyN/A -115.67% -84.82% Humacyte N/A N/A -78.26% SummaryHumacyte beats ALX Oncology on 10 of the 14 factors compared between the two stocks. Get ALX Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for ALXO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALXO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALXO vs. The Competition Export to ExcelMetricALX OncologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$57.83M$3.12B$5.77B$9.92BDividend YieldN/A2.29%6.71%4.51%P/E Ratio-0.557.5556.5522.02Price / SalesN/A466.49534.30112.03Price / CashN/A44.9736.9659.01Price / Book0.579.8611.446.09Net Income-$134.85M-$53.47M$3.28B$266.14M7 Day Performance4.27%2.89%0.84%0.28%1 Month Performance84.54%8.62%7.15%4.14%1 Year Performance-38.69%13.69%59.66%23.93% ALX Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALXOALX Oncology4.0372 of 5 stars$1.22+13.0%$3.30+170.5%-47.6%$57.83MN/A-0.5540News CoverageShort Interest ↓Gap DownHUMAHumacyte2.7966 of 5 stars$1.50-5.1%$10.64+609.5%-74.3%$250.23M$1.57M0.00150SOPHSOPHiA GENETICS2.1286 of 5 stars$3.45-4.4%$8.00+131.9%-9.3%$243.96M$65.17M-7.84520News CoverageShort Interest ↑FENCAdherex Technologies1.5944 of 5 stars$8.65-0.1%$13.33+54.1%+65.1%$240.87M$47.54M-20.5910TLSATiziana Life Sciences0.2779 of 5 stars$1.96-4.9%N/A+71.7%$240.71MN/A0.008Gap UpAVTEAerovate TherapeuticsN/A$8.23+11.5%N/A-88.7%$238.55MN/A-2.7520News CoveragePositive NewsHigh Trading VolumePRQRProQR Therapeutics2.871 of 5 stars$2.25-0.4%$8.00+255.6%+26.1%$237.78M$20.46M-4.89180Positive NewsTRDAEntrada Therapeutics3.1474 of 5 stars$5.63-8.3%$25.67+355.9%-66.1%$233.55M$210.78M0.00110News CoveragePositive NewsSGMTSagimet Biosciences3.8296 of 5 stars$7.08-0.4%$25.67+262.5%+151.7%$231.23M$2M-3.878ENGNenGene3.0218 of 5 stars$4.30-0.5%$23.29+441.5%-24.4%$220.77MN/A0.0031Upcoming EarningsShort Interest ↓GNFTGENFIT1.7894 of 5 stars$4.19-4.5%$9.00+115.1%-8.8%$219.08M$76.77M0.00120Positive News Related Companies and Tools Related Companies Humacyte Competitors SOPHiA GENETICS Competitors Adherex Technologies Competitors Tiziana Life Sciences Competitors Aerovate Therapeutics Competitors ProQR Therapeutics Competitors Entrada Therapeutics Competitors Sagimet Biosciences Competitors enGene Competitors GENFIT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALXO) was last updated on 9/5/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ALX Oncology Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ALX Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALXO Stock Alerts